SLU-PP-332

SLU-PP-332 (Oral)

SLU‑PP‑332 is a research small molecule/ligand (often discussed alongside peptide/small‑molecule performance metabolism research) reported as an estrogen‑related receptor (ERR) agonist that may increase oxidative metabolism and endurance phenotypes in preclinical studies. It is not an approved drug, and human dosing data are not established.

Dosing Protocols

Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
Murine research dose range: 1250–2500 mcg daily (for a 25 g mouse), administered in two divided doses. Human equivalent dosing not established.
Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.
Storage: Lyophilized: −20 °C; reconstituted: refrigerate at 2–8 °C.

Schedule: 8 weeks in published studies (murine).
Cycle Length: 8 weeks in published studies.
Goal: Preclinical research compound — human dosing protocols not established.

Frequency: Not established for human use. Preclinical research only.

Phase	Dose	Syringe (U-100)
Research reference dose (mouse)	1250–2500 mcg/day	Divided into 2 doses

Benefits

• In preclinical studies, increased oxidative (mitochondrial) metabolism in skeletal muscle
• Reported endurance-like performance phenotype in animal models
• May increase fatty acid oxidation gene programs via ERR pathways
• Potential support for metabolic flexibility (preclinical)
• Investigated for possible utility in obesity/metabolic disease models (preclinical)
• May influence cardiac and skeletal muscle mitochondrial biogenesis programs (preclinical)

Mechanism of Action

Reported to activate estrogen‑related receptors (ERRα/ERRγ) and downstream transcriptional programs involved in mitochondrial oxidative phosphorylation, fatty acid oxidation, and energy expenditure. ERR activation can upregulate PGC‑1α-linked pathways, increasing mitochondrial content/function and shifting substrate utilization toward oxidative metabolism.

Side Effects

• Unknown in humans (no established safety profile)
• Potential nausea/GI upset
• Headache
• Insomnia or jitteriness (possible with metabolic stimulants)
• Elevated heart rate/blood pressure (theoretical)
• Changes in liver enzymes (theoretical)

Side Effect Management

• Avoid human self-experimentation; if used in research contexts, prioritize lowest effective dose in model systems
• Monitor body weight, activity, and biomarkers in controlled studies
• Stop exposure if signs of stress/toxicity appear
• Avoid combining with other metabolic stimulants in exploratory studies

Contraindications

• Human use (not approved; insufficient data)
• Pregnancy/breastfeeding (unknown risk)
• Cardiovascular disease (theoretical risk)
• Hepatic impairment (theoretical)

Research Citations

PubMed/DOI-linked citations for verification. Many studies are preclinical (animal/in-vitro) or early clinical.

1. A potent ERR agonist induces an exercise-like metabolic program in mice (SLU-PP-332 reported in preclinical literature). DOI Link
2. Estrogen-related receptors in metabolism and mitochondrial biogenesis (ERR review). DOI Link
3. PGC-1α and the regulation of mitochondrial metabolism (review). DOI Link

---